|
| Press Releases |
|
 |
|
| Wednesday, June 10, 2020 |
|
|
Eisai to Support Counter-Measures Against the Spread of the Novel Coronavirus Infection in Africa |
| Eisai Co., Ltd. announced today that it has committed the equivalent of 1 million USD in aid towards various activities in response to the spread of the novel coronavirus infection in Africa, beginning with the activities described below. more info >> |
|
| Thursday, June 4, 2020 |
|
|
Eisai: Brain Performance (Brain-Health) Self-Check Tool "NouKNOW" to be Used in Beauty Salons |
| Eisai Co., Ltd. announced today that the digital tool for self-assessment of brain performance (brain health) "NouKNOWTM", which Eisai has launched in Japan, is to be expanded in the fixed-rate membership beauty salon "Attina", which is operated by Youforio Co., Ltd. more info >> |
|
| Tuesday, June 2, 2020 |
|
|
Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020. more info >> |
|
| Friday, May 29, 2020 |
|
|
AbbVie and Eisai Announce an Approval for Partial Changes in the Marketing Approval of HUMIRA, a Fully Human Anti-TNFalpha Monoclonal Antibody |
| AbbVie GK and Eisai Co., Ltd. today announced an approval of partial changes in the marketing approval of HUMIRA (generic name: adalimumab [recombinant], hereafter "HUMIRA"), a fully human anti-TNFalpha monoclonal antibody, for additional dosage and administration, specifically, to add an 80mg every-other-week (Q2W) regimen as a treatment option for patients with hidradenitis suppurativa (HS) after the first 4 weeks of treatment. more info >> |
|
|
Eisai: Results from LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Trials |
| The two trials, Study 116/KEYNOTE-524 and Study 111/KEYNOTE-146, examined patients with unresectable hepatocellular carcinoma (HCC) with no prior systemic therapy and patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy, respectively. more info >> |
|
| Monday, May 18, 2020 |
|
|
Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules |
| Eisai Co., Ltd. announced today that it has launched New Selbelle Premium Tablets and New Selbelle Premium Fine Granules (both are category-2 OTC drug, "New Selbelle Premium") on May 18, 2020. more info >> |
|
| Thursday, May 14, 2020 |
|
|
Eisai to Present Data on Oncology Pipeline and Products at ASCO20 Annual Meeting |
| Eisai Co., Ltd. announced today that presentations on a series of abstracts regarding its in-house discovered lenvatinib mesylate and eribulin mesylate will be given at the American Society of Clinical Oncology, from May 29 to 31, 2020. more info >> |
|
| Monday, April 27, 2020 |
|
|
Eisai Selected as Most Honored Company and the First Place of the Sector in "The All-Japan Executive Team (Best IR Company Ranking)" by Institutional Investor Magazine |
| This selection is based on Eisai's being ranked first place in "Best CEOs" and "Best CFOs", respectively, in the sector. more info >> |
|
| Wednesday, April 1, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in China |
| Eisai Co., Ltd. and Seikagaku announced today that the companies have entered into an agreement for the co-development and marketing alliance in China for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. more info >> |
|
| Thursday, March 26, 2020 |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Denileukin Diftitox (Genetic Recombinant) |
| Eisai Co., Ltd. announced today that it has submitted in Japan a marketing authorization application of the anticancer agent denileukin diftitox (genetic recombinant) (generic name, development code: E7777) for relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) and Peripheral T-cell Lymphoma (PTCL). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Buy International Homes at the Global Property Expo, Singapore
Jul 14, 2025 14:48 HKT/SGT
|
|
|
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
|
|
|
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
|
|
|
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
|
|
|
Bluemount Holdings Limited Announces Pricing of $5.5 Million Initial Public Offering
Jul 11, 2025 08:28 HKT/SGT
|
|
|
ZA Miner Launches AI-Powered Bitcoin Mining Contracts, Marking Milestone in Cloud Mining Innovation 
Jul 11, 2025 07:00 HKT/SGT
|
|
|
XDS Datacentres and ICS Arabia partner to launch landmark 10MW Immersive Cooling Data Center in KSA
Jul 11, 2025 06:00 HKT/SGT
|
|
|
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models
Jul 10, 2025 23:00 HKT/SGT
|
|
|
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
|
|
|
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
|
|
|
The 10th Quam IR Awards was Successfully Held
Jul 10, 2025 15:12 HKT/SGT
|
|
|
Tianci International: Discussing Strategic Opportunities for the Shipping and Logistics Industry to Integrate with Blockchain Technology and RWA
Jul 10, 2025 12:30 HKT/SGT
|
|
|
Tradable Bits Powers Fan Engagement for Rugby Australia's Hosting of the Qatar Airways British & Irish Lions Men's Tour 2025
Jul 10, 2025 07:30 HKT/SGT
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00 HKT/SGT
|
|
|
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany
Jul 9, 2025 22:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
